OBJECTIVE:To report on the development, validation, and clinical outcomes of 876 consecutive cases of prenatal diagnosis of rare monogenic diseases using celocentesis. METHODS:This retrospective single-center study, conducted between April 2006 and December 2025, evaluated celomic fluid collected at 7-9 weeks of gestation from women at risk of carrying fetuses with monogenic diseases. Fetal DNA was obtained by isolating embryo-fetal erythroid precursors. All samples were assessed for the presence of parental molecular defects and maternal cell contamination (MCC). RESULTS:The median gestational age at the time of celocentesis was 8.4 weeks. Successful aspiration of celomic fluid was achieved in 875/876 cases (99.9%). Although MCC was observed in 98.74% of the samples, an initial subset of 19/190 (10%) was found unsuitable for molecular analysis. Subsequently, an optimized molecular workflow was successfully applied to the remaining cohort, achieving a success rate of 98% (671/685 procedures). Results were validated against confirmatory samples from abortive tissue (following VIP), amniotic fluid, or postnatal blood. All cases were correctly classified, demonstrating 100% sensitivity and specificity. CONCLUSION:This study supports the clinical application of celocentesis as a reliable early prenatal diagnostic procedure for monogenic diseases. It represents a viable alternative to Chorionic Villus Sampling (CVS) and amniocentesis, enabling invasive prenatal diagnosis at a significantly earlier stage of pregnancy.
Venetoclax combined with azacitidine has transformed the treatment of newly diagnosed acute myeloid leukemia in patients ineligible for intensive chemotherapy. However, prolonged cytopenias, infectious complications, and treatment interruptions have prompted increasing use of abbreviated venetoclax schedules. This narrative review critically examines the evidence supporting modifications in treatment duration and daily dose, with emphasis on the balance between antileukemic efficacy and tolerability. Retrospective studies, including the analysis by Willekens and colleagues, suggest that shorter schedules may reduce selected measures of hematologic toxicity and supportive-care burden while maintaining encouraging remission rates. Nevertheless, these findings are vulnerable to selection bias and cannot establish equivalence. Importantly, the randomized OPTI-AML trial did not demonstrate noninferiority of a 14-day induction schedule compared with 28 days and identified a potentially relevant reduction in early complete remission among patients harboring NPM1 and/or IDH2 mutations. These observations suggest that the consequences of shortening venetoclax exposure may depend on treatment phase and leukemia biology. We discuss pharmacokinetic interactions, post-remission cytopenia management, and molecularly informed treatment adaptation, and highlight the need for prospective studies that jointly evaluate efficacy, toxicity, and patient-centered outcomes.
BackgroundEarly hospital discharge has shifted complex care to domestic settings, increasing the risk of Healthcare-Associated Infections (HAIs). This review evaluates home care HAI prevalence, risk factors, and preventive challenges.MethodsFollowing PRISMA guidelines, a systematic search identified original studies on adult home care patients. Methodological quality was assessed using the RTI Item Bank and MMAT.ResultsTen studies were included in the narrative synthesis. Findings suggest that the overall prevalence of HAIs in the home care setting varies widely depending on reporting criteria and specific populations, also highlighting a critical epidemiological shift. In fact, up to 56% of home-managed HAIs were imported from previous hospitalizations thus actively introducing Multidrug-Resistant Organisms (MDROs)—such as ESBL-producing E. coli and Clostridium difficile—into the community setting. The prolonged use of invasive medical devices (e.g., urinary catheters, implantable ports), combined with severe chronic comorbidities like dementia, diabetes, and hypoalbuminemia, strongly amplifies infection risks. Furthermore, adherence to standard Infection Prevention and Control (IPC) protocols is frequently hindered by structural barriers, including a lack of cleanliness (85.4%) and space (77.1%). In this unregulated setting, the capability and education of informal caregivers act as primary determinants of infection outcomes.ConclusionThe home care environment is increasingly vulnerable to severe HAIs. Mitigating these risks requires the development of setting-specific IPC guidelines and the formal integration of caregiver education into public health policies.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42024594811, identifier PROSPERO (CRD42024594811).
Background/Objectives: This study aimed to review current evidence on celocentesis as an early invasive prenatal diagnostic technique, focusing on its clinical applications, diagnostic accuracy, safety profile, and future perspectives in modern fetal medicine. Methods: A narrative review of the literature was conducted through PubMed and Scopus databases up to October 2025. Studies reporting original data on celocentesis-including prospective studies, case reports, and case series-were included. Relevant outcomes were feasibility, safety, and diagnostic accuracy. Results: Since its first description in 1993, celocentesis has been successfully performed between 6 and 9 weeks' gestation in several small case series. Improvements in ultrasound resolution and molecular analysis techniques have significantly enhanced its reliability. In specialized centers using dedicated fetal cell selection and contamination-control workflows, analytical diagnostic success for selected monogenic conditions exceeds 99%. Reported miscarriage rates are comparable to what is expected at a very early gestational age (10% of all clinically recognized pregnancies). The procedure remains mainly experimental, with no standardized protocols or large multicentric validation. Conclusions: Celocentesis is the earliest available technique for prenatal genetic diagnosis. While promising, its clinical implementation requires further standardization, comprehensive operator training, and robust evidence from prospective studies regarding its safety and diagnostic reliability.
This expert consensus aims to define how 2-deoxy-2-[18 F]-fluoro-D-glucose ([¹⁸F]FDG) positron emission tomography/computed tomography (PET/CT) can be systematically integrated into clinical pathways for early identification of diffuse large B-cell lymphoma (DLBCL) patients who may benefit from chimeric antigen receptor T-cell (CAR-T) therapy. The main research question is how PET-derived parameters and timing can optimize risk stratification and guide timely referral for advanced therapies. A multidisciplinary panel of nuclear medicine physicians and hematologists conducted a structured consensus process based on current literature, international guidelines, and expert discussion. Key clinical scenarios and statements were evaluated across multiple meetings to assess the role of PET/CT at baseline, interim, and end-of-treatment stages. PET/CT provides critical prognostic information throughout the disease course. Baseline quantitative metrics (e.g., metabolic tumor volume) improve risk stratification beyond conventional indices. Interim PET, particularly using Deauville score and the change in the maximum standardized uptake value, enables early identification of high-risk or refractory patients. End-of-treatment PET remains essential for response assessment and therapeutic decision-making. Standardization of acquisition, reporting, and interpretation is necessary to enhance reproducibility and clinical integration. PET/CT should be considered a central biomarker in DLBCL management, enabling earlier identification of high-risk patients and facilitating timely CAR-T referral. Harmonized, multidisciplinary implementation is essential to optimize outcomes and improve access to potentially curative therapies.